{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:05:00Z","timestamp":1767845100466,"version":"3.49.0"},"reference-count":25,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health, Australian Government | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1047105"],"award-info":[{"award-number":["APP1047105"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Dried blood spot (DBS) antibiotic assays can facilitate pharmacokinetic\/pharmacodynamic (PK\/PD) studies in situations where venous blood sampling is logistically and\/or ethically problematic. In this study, we aimed to develop, validate, and apply a DBS ceftriaxone assay. A liquid chromatography-tandem mass spectroscopy (LC-MS\/MS) DBS ceftriaxone assay was assessed for matrix effects, process efficiency, recovery, variability, and limits of quantification (LOQ) and detection (LOD). The effects of hematocrit, protein binding, red cell partitioning, and chad positioning were evaluated, and thermal stability was assessed. Plasma, DBS, and cell pellet ceftriaxone concentrations in 10 healthy adults were compared, and plasma concentration-time profiles of DBS and plasma ceftriaxone were incorporated into population PK models. The LOQ and LOD for ceftriaxone in DBS were 0.14 mg\/liter and 0.05 mg\/liter, respectively. Adjusting for hematocrit, red cell partitioning, and relative recovery, DBS-predicted plasma concentrations were comparable to measured plasma concentrations (\n            <jats:italic>r<\/jats:italic>\n            &gt; 0.95,\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.0001), and Bland-Altman plots showed no significant bias. The final population PK estimates of clearance, volume of distribution, and time above threshold MICs for measured and DBS-predicted plasma concentrations were similar. At 35\u00b0C, 21\u00b0C, 4\u00b0C, \u221220\u00b0C, and \u221280\u00b0C, ceftriaxone retained &gt;95% initial concentrations in DBS for 14 h, 35 h, 30 days, 21 weeks, and &gt;11 months, respectively. The present DBS ceftriaxone assay is robust and can be used as a surrogate for plasma concentrations to provide valid PK and PK\/PD data in a variety of clinical situations, including in studies of young children and of those in remote or resource-poor settings.\n          <\/jats:p>","DOI":"10.1128\/aac.01740-15","type":"journal-article","created":{"date-parts":[[2015,10,6]],"date-time":"2015-10-06T02:28:33Z","timestamp":1444098513000},"page":"14-23","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":30,"title":["Validation and Application of a Dried Blood Spot Ceftriaxone Assay"],"prefix":"10.1128","volume":"60","author":[{"given":"Madhu","family":"Page-Sharp","sequence":"first","affiliation":[{"name":"School of Pharmacy, Curtin University, Bentley, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy","family":"Nunn","sequence":"additional","affiliation":[{"name":"Department of Medicine, Fremantle Hospital, Fremantle, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam","family":"Salman","sequence":"additional","affiliation":[{"name":"School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brioni R.","family":"Moore","sequence":"additional","affiliation":[{"name":"School of Medicine and Pharmacology, University of Western Australia, Harry Perkins Research Institute, Fiona Stanley Hospital, Murdoch, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin T.","family":"Batty","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Curtin University, Bentley, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M. E.","family":"Davis","sequence":"additional","affiliation":[{"name":"School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurens","family":"Manning","sequence":"additional","affiliation":[{"name":"School of Medicine and Pharmacology, University of Western Australia, Harry Perkins Research Institute, Fiona Stanley Hospital, Murdoch, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/510079"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/520991"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200104000-00010"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2011.02.005"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.3.994-1000.2006"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200342150-00007"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10156-007-0539-2"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200310000-00009"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-0807"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1086\/588049"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.10.080010"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.4155\/bio.11.235"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2010.07.015"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2011.03.017"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2011.12.018"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2008.09.025"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2008.04.003"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1021\/ac020361s"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1570-0232(03)00209-5"},{"key":"e_1_3_2_21_2","first-page":"101","volume-title":"Pharmaceutics: the science of dosage form design","author":"Pugh J","year":"2002","unstructured":"Pugh J. 2002. Kinetics and product stability, p 101\u2013112. In Aulton M (ed), Pharmaceutics: the science of dosage form design, 2nd ed. Churchill Livingstone, Edinburgh, United Kingdom.","edition":"2"},{"key":"e_1_3_2_22_2","volume-title":"Martin's physical pharmacy and pharmaceutical sciences","author":"Sinko P","year":"2011","unstructured":"Sinko P. 2011. Martin's physical pharmacy and pharmaceutical sciences, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.","edition":"6"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.24.25"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.2.192"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.21.6.957"},{"key":"e_1_3_2_26_2","volume-title":"Document M100-S24","author":"Clinical and Laboratory Standards Institute","year":"2014","unstructured":"Clinical and Laboratory Standards Institute. 2014. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. Document M100-S24. Clinical and Laboratory Standards Institute, Wayne, PA."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01740-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01740-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:32:21Z","timestamp":1645475541000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01740-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1128\/AAC.01740-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.01740-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"2015-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-10-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}